The treatment landscape for advanced urothelial cancer is rapidly evolving and expanding. Identifying optimal therapies is key to optimizing patient outcomes. Read this commentary on important considerations for managing patients with advanced urothelial cancer using the most recent therapeutic advances available for these patients.
Oncology NPs, PAs, and nurses
This activity is supported by an educational grant from Seagen Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103421GUBC-CTB